Introduction
Saccharomyces cerevisiae CDMO services represent a matured, high-performance platform for vaccines, nutraceutical proteins, Fc-fusion constructs, and other biologics that benefit from eukaryotic post-translational modifications and well-understood regulatory history. With decades of clinical precedent and global regulatory familiarity, Saccharomyces cerevisiae CDMO services deliver both scientific depth and manufacturability discipline. Whether your molecule demands glycosylation, secretion, or scale—with cost and quality in mind—this yeast chassis offers a compelling trade-space between microbial speed and mammalian complexity.
In these Saccharomyces cerevisiae CDMO services, we unite advanced strain engineering, precision fermentation, downstream purification, and robust analytics into a commercial-ready workflow. This page outlines our full offering—from cell bank design to commercial GMP supply—highlighting why this platform remains a strategic choice for next-generation biologics.
Why Saccharomyces cerevisiae?
Biological Advantages
- Yeast Eukaryotic Folding & Secretion: Unlike many bacteria, S. cerevisiae offers a eukaryotic secretory pathway, enabling proper disulfide bonding and secretion of complex proteins.
- Modular Glycosylation Options: While wild-type S. cerevisiae produces high-mannose N-glycans, modern glyco-engineering allows humanised or simplified glycoforms, aligning with Fc-fusion and vaccine antigens.
- Robust Growth & Scalable Fermentation: Capable of high-cell-density growth in defined media, yeast cultures reach high biomass in fed-batch mode with reliable oxygen transfer.
- Regulatory Precedent & Safety: Saccharomyces cerevisiae has been used for vaccines, adjuvant proteins, and biologics for years, which smooths the regulatory interface and risk assessment.
Manufacturability Strengths
- Rapid Strain Development: CRISPR/Cas9 and multiplex editing enable strain optimisation within weeks (versus months in mammalian systems).
- Fed-Batch / High Density: Optimised kLa control, DO set-points, feeding regimes (glucose, glycerol, ethanol) produce consistent titers.
- Scalable Equipment: Single-use and stainless-steel bioreactors from 50 L to 2,000 L plus downstream suite minimise scale-up risk.
- Downstream Purification Benefit: Secretion simplifies harvest (centrifugation/filtration) compared to inclusion body systems; downstream chromatography is more tractable.
Our Saccharomyces cerevisiae CDMO Service Workflow
Cell Bank & Strain Engineering
- Master and Working Cell Banks: GMP-qualified banks with full documentation, stability testing, STR identity, mycoplasma, and viral clearance.
- Promoter Selection & Signal Peptide Ladder: TEF1, PGK1, GAL1, MET25 promoters used; signal peptides (α-factor, SUC2, acid phosphatase) screened in parallel to optimise secretion.
- Copy‐Number Tuning & Integration Site Characterisation: Multi-integration at HIS3, URA3 loci; targeted to avoid genomic hot-spots and reduce transcriptional silencing.
- Glyco-Engineering Optionality: Clients may choose wild-type glycosylation, hypo-mannosylated, or humanised N-glycan pathways (e.g., deletion of OCH1, introduction of human glycosyltransferases).
- Process Analytics Integration: Early small-scale fermentations (2–10 L) instrumented with DO, pH, biomass (OD/TC), metabolites (lactate, ethanol), enabling DOE (Design of Experiments) phase.
Upstream Process Development
- Media & Feeding Strategy: Defined media (YPD/SC) shifts to chemo-defined feeds; fed-batch yields maximised via glycerol feeding then glucose pulse.
- Oxygen Transfer & kLa Control: With yeast’s high respiratory demand, we optimise agitation and sparging (microbubbles, internal loop) to maintain >80% DO.
- Shear Sensitivity Analysis: Proteins with fragile disulfides are monitored under agitation; impeller design tuned for low shear stress.
- Scale-Up Strategy: From 10 L → 200 L → 2,000 L with scale-down models verifying equivalent mixing and oxygen transfer parameters.
- Inline Analytics: Real-time biomass (via spectroscopy), off-gas CO₂/O₂ ratios, and metabolite sensors permit adaptive feeding.
Downstream & Purification
- Harvest Strategy: For secreted products, continuous centrifugation or depth filtration to remove cells; intracellular recoveries include bead-mill or high-pressure homogenisation.
- Clarification & Capture: Depth filters, TFF or UF/DF as first step; capture via HIC, IMAC, or Protein A if Fc-tagged.
- Polishing & Viral Clearance: Ion-exchange chromatography, size-exclusion chromatography, Planova® 20N filter for viral reduction (though yeast has low viral risk).
- Glycan/Impurity Profiling: LC–MS glycan mapping to validate glyco-engineering goals; HCP and DNA clearance to <100 ppm standard.
- Formulation & Fill-Finish: Interfaces with our formulation teams ensure compatibility (pH, surfactant, excipients) and ready for sterile fill.
Analytical & Method Validation
- Structural Characterisation: MS/LC–MS peptide mapping, CD (circular dichroism) for folding, DSC for Tm.
- Quality Attributes: SDS-PAGE/CE-SDS, SEC-MALS for aggregation, glycan maps via HILIC-UPLC.
- Potency Assays: Cell-based binding (e.g., Fc-R binding for Fc-fusion), antigenicity ELISA for vaccine antigens.
- Stability Studies: ICH-compliant accelerated and real-time; forced-degradation studies to identify degradation pathways.
- Comparability and Lifecycle Management: Change controls facilitated by robust analytics and digital QMS.
Tech Transfer & GMP Manufacturing
- Documentation Package: Process description (PFDs/P&IDs), validation summary, batch records, deviation/CAPA logs.
- Quality Systems: cGMP compliant (21 CFR Part 210/211), ISO 13485 for vaccines, audit-ready QA/RA support.
- Commercial Scale: Bioreactors (500 L–2,000 L+), downstream trains, batch capacities aligned with client’s market forecasts.
- Supply Chain: Qualified raw materials, back-up fermentor capacity, global logistics (cold-chain, ambient formats).
- Regulatory Support: Data packets for IND/IMPD, MAA, DS/DP comparability; pre-submission meetings supported.
Applications & Use-Cases
- Vaccines: Subunit antigens (toxoid, viral proteins) expressed and secreted, often requiring glycosylation and high purity.
- Nutraceuticals & Food Proteins: High-yield secreted enzymes or nutritional proteins produced cost-effectively in yeast chassis.
- Fc-Fusion Constructs: Therapeutic cytokine receptors or ligand–Fc fusions harness secretion and glyco-engineering capability.
- Industrial Enzymes: Yeast expression offers secretion and cost-effectiveness vs mammalian systems—ideal for diagnostics, IVD, and bio-industrial use.
Competitive Differentiators
Strain breadth & customisation
Saccharomyces cerevisiae CDMO services excel when the chassis palette is wide and well-characterised. We maintain multiple library strains (laboratory, industrial, protease-deficient, hypo-mannosylating, auxotrophic, and antibiotic-free) with documented performance across secretion, intracellular expression, and membrane display. For each program we tune promoter architecture (TEF1, TDH3, PGK1, GAL1, MET25), signal peptides (α-factor prepro, SUC2, PHO5), and copy number (single-locus integration vs multi-copy δ-integration) using CRISPR/Cas9 or integrase systems. Strain selection is driven by titer–quality–processability (TQP) trade-offs quantified in parallel at micro-bioreactor, 2–10 L, and 50–200 L scales. This depth enables Saccharomyces cerevisiae CDMO services to present ready-to-scale lineages for both clinical and commercial campaigns.
Yeast-specialist team
Generalists struggle where yeast-specific pitfalls dominate (oxygen demand, glyco-microheterogeneity, cell-wall shear, proteases). Our teams build DOE matrices that explicitly span kLa windows, ethanol/glucose co-feeding, and nitrogen limitation regimes; they also design scale-down models that replicate large-tank mixing times and gas–liquid mass transfer.
Expect hard numbers on oxygen uptake rate (OUR), specific productivity (qP), and carbon balance—not anecdotes. This specialist focus is why Saccharomyces cerevisiae CDMO services routinely deliver faster process lock and fewer post-lock surprises than cross-modality shops.
Glyco-engineering capability
Wild-type S. cerevisiae tends toward hyper-mannosylation; that’s a feature for some antigens and a bug for many Fc-fusions. Our glyco-toolbox supports OCH1 deletion, MNN1/MNN9 tuning, human glycosyltransferase cassettes, and terminal sialylation pathways where required. We confirm outcomes by HILIC-UPLC and LC–MS glycan mapping, quantify site occupancy, and correlate glycoforms with FcγR binding, ADCC/CDC surrogates, or antigenicity.
The net effect: Saccharomyces cerevisiae CDMO services that keep you in yeast while achieving “mammalian-like enough” profiles—avoiding costly host switches.
Scalable pathways with line-of-sight to supply
Scale-up is engineered, not improvised. We progress 10 L → 200 L → 1,000–2,000 L with constant volumetric power input (P/V) and matched kLa targets, then verify with scale-down stress tests (gas flow perturbations, feed bolus excursions, agitation spikes). PAT includes off-gas analytics (CO₂/O₂), capacitance biomass, Raman for substrates, and automated feed controllers. The result is a documented path from lab to multi-kilolitre with predictable cost-of-goods. Saccharomyces cerevisiae CDMO services stand or fall on scale discipline; ours is codified in tech-transfer packages regulators can follow.
Regulatory confidence
Yeast carries a favourable viral safety profile and deep clinical precedent across vaccines and recombinant proteins. Our Saccharomyces cerevisiae CDMO services align with ICH Q5/Q6, deliver viral-like particle risk rationales, and package comparability protocols that survive agency scrutiny. Lower adventitious-agent risk means fewer detours, fewer assays, and cleaner narratives in IND/IMPD sections.
Technical Considerations & Risk Mitigation
Glycosylation heterogeneity
Without intervention, high-mannose glycans (Man₈–Man₁₂) proliferate. We deploy targeted glyco-pathway edits, fermentation set-points that modulate glycan processing (DO, pH, carbon flux), and post-expression endo-trim options when appropriate. Analytics: exoglycosidase arrays, MALDI-TOF, and HPAEC-PAD for monosaccharide ratios. Saccharomyces cerevisiae CDMO services need to tie glycoform to function; we do so with Fc receptor panels or antigen binding kinetics (SPR/BLI).
Protease activity
Secreted proteases (e.g., yapsins) can clip C-terminal tails or linkers. We combine protease-knockout strains, signal-peptide ladders that re-time secretion, in-fermentor pH/temperature set-points that reduce protease activity, and protease inhibitor-free downstream where possible. Cleavage maps are built by peptide mapping LC–MS; fixes are verified with stability-indicating assays.
Oxygen demand & mass transfer
High-density yeast requires aggressive oxygen transfer. We design for kLa ≥0.4–0.6 h⁻¹ using micro-sparging, pure-oxygen blends, and high-efficiency Rushton/Michel impellers (or low-shear hydrofoils for sensitive products). Real-time OUR and dynamic gassing maintain DO without ethanol overflow metabolism. Saccharomyces cerevisiae CDMO services that quantify kLa and OUR up front shorten the “why did it crash at 1,000 L?” post-mortems later.
Shear & cell-wall stress
Fragile, disulfide-rich proteins and Fc-fusions can suffer under high tip speeds. We characterise shear sensitivity at benchtop using controlled impeller sweeps, then set maximum tip-speed envelopes for scale. Harvest uses gentle depth filtration or low-g centrifugation; no-foam or low-foam antifoams are pre-screened for leachables/extractables.
Host-cell impurity profiles
Yeast HCPs and glucans differ from bacterial/mammalian impurities. Our DSP couples AEX/CEX polishing, SEC-MALS aggregation control, β-glucan assays, and DNA qPCR to sub-ppm levels. We qualify clearance with spike–recovery studies and build platform clearance claims to reduce program-specific rework—key to efficient Saccharomyces cerevisiae CDMO services.
Expanded Case Study Snapshot
Objective
A Phase II sponsor required a secreted Fc-fusion cytokine trap with human-compatible glycoforms, stability at 2–8 °C, and a COGS compatible with global access pricing. They mandated a yeast route and selected our Saccharomyces cerevisiae CDMO services.
Approach
- Strain engineering: δ-integration (10–15 copies), α-factor prepro signal; OCH1Δ / MNN1Δ background with human GnT I/II pathway.
- Screening: 96-well micro-bioreactors → 2 L DoE covering feed carbon (glycerol/glucose), DO (40–85%), pH (5.2–6.2).
- Upstream lock: Fed-batch at 200 L, kLa = 0.5 h⁻¹, mixed carbon strategy avoiding Crabtree effect.
- DSP: Protein A capture (Fc handle), AEX polishing, UF/DF to final buffer; SEC-MALS to verify monomericity >98.5%.
- Analytics: HILIC-UPLC glycan maps, SPR FcγRIIIa binding, capillary isoelectric focusing, DSC Tm = 64.8 °C.
- Stability: ICH Q1A accelerated/real-time; 12-month 2–8 °C met potency and aggregation specs.
Outcomes
- 10 L: 2.1 g/L; 200 L: 8.0 g/L; 1,000 L tech-transfer validated in 12 weeks.
- HCP < 50 ppm, DNA < 10 ng/dose, endotoxin < 1 EU/mg.
- Comparability accepted for a formulation buffer swap; IND amendment cleared on first round.
This arc illustrates how Saccharomyces cerevisiae CDMO services compress timeline risk by solving glycoform, oxygen, and protease problems early—then carrying that logic intact to kilo-litre scale.
Sustainability & Cost Efficiency
Saccharomyces cerevisiae CDMO services deliver structural economics that are hard to beat:
- Media cost & complexity: Chemically defined media; no serum or complex supplements.
- Doubling time: ~90–120 min supports rapid seed trains and high facility throughput.
- Cell density: > 100 g CDW/L achievable; oxygen strategy prevents overflow metabolism.
- Utilities & waste: Lower bioburden risk, simpler CIP/SIP than mammalian; single-use options reduce cleaning validation.
- Feedstocks & ESG: Glycerol, sugar-cane hydrolysate, and side-stream valorisation reduce scope-3 emissions. We model COGS under multiple energy and raw-material scenarios and provide LCAs upon request.
By design, Saccharomyces cerevisiae CDMO services couple lower COGS with smaller carbon footprints—useful in pricing negotiations and sustainability reporting.
Saccharomyces FAQ
*Technical reference for researchers, process engineers, and biotech founders seeking depth and detail.
Introduction
Saccharomyces cerevisiae remains one of biotechnology’s most deeply characterised and adaptable chassis organisms. Yet, scaling a program from gene to GMP requires nuance: glycoforms, secretion bottlenecks, protease activity, oxygen transfer, regulatory dossiers—all converging on one platform. Below are twenty advanced questions our clients and collaborators most often ask about Saccharomyces cerevisiae CDMO services, with detailed answers from a scientific and process-engineering perspective.
1. Can Saccharomyces cerevisiae produce mammalian-grade glycoproteins?
Yes. Through OCH1 deletion and introduction of heterologous glycosyltransferases (GnT I/II, mannosidase II, β-1,4-galactosyltransferase, and sialyltransferases), yeast can generate hybrid or humanised N-glycans. Elise Biopharma validates these via HILIC-UPLC and LC-MS mapping. Site occupancy is tuned by DO control and carbon feed to balance ER processing load.
2. How does Elise manage hyper-mannosylation?
We combine genetic edits (ΔOCH1, ΔMNN1, ΔMNN9) with controlled pH (5.0–5.6) and dissolved oxygen >70% to favour trimmed glycans. Enzymatic post-processing with Endo H or α-mannosidase is optional. Our platform reduces heterogeneity from Man₁₂–Man₁₄ to Man₈–Man₉ baseline.
3. What secretion signals perform best for Fc-fusions or disulfide-rich proteins?
The α-factor pre-pro leader remains the workhorse, but hybrid constructs (α-factor pre-pro fused with SUC2 signal) often outperform for Fc-domains. We test up to six signal variants per candidate, quantified via ELISA and SDS-PAGE densitometry.
4. Can you integrate multi-copy genes without plasmid instability?
Yes. We favour δ-element integration and CRISPR-driven copy insertion at defined loci. Up to 12 stable copies have been demonstrated without metabolic burden. Selectable markers (URA3, HIS3) are recycled via Cre-lox or marker-loopout cassettes.
5. What fermentation mode gives the best yield for secreted products?
Fed-batch in semi-defined media with mixed carbon feeding (glycerol → glucose → ethanol) produces >8 g/L titers for most constructs. Continuous cultures are possible for enzyme products but risk protease buildup.
6. How is oxygen transfer optimised at scale?
S. cerevisiae is strongly respiratory; we target kLa = 0.4–0.6 h⁻¹. Bioreactors are equipped with micro-spargers, segmented baffles, and DO-cascade agitation control. Elise correlates off-gas CO₂/O₂ with OUR to predict shifts before Crabtree metabolism occurs.
7. Does yeast glycosylation affect immunogenicity in vaccine antigens?
Sometimes beneficially. High-mannose glycans can act as pathogen-associated motifs that enhance dendritic uptake. For subunit vaccines, we characterise immunogenic potential with PBMC assays and glycan masking studies.
8. How is protease activity mitigated?
We employ protease-deficient strains (ΔPRB1, ΔYPS1–7), mild induction temperatures (25–28 °C), and pH 6.0–6.5 fermentation to suppress aspartyl protease activity. Proteolysis mapping (LC-MS) guides further edits.
9. Are Fc-fusions expressed with intact disulfide bonding?
Yes. The ER oxidative folding environment supports correct pairing. Disulfide integrity is confirmed via non-reducing SDS-PAGE and peptide mapping. When needed, PDI1 and ERO1 overexpression enhances folding kinetics.
10. What purification methods work best for secreted yeast proteins?
Depth filtration → UF/DF → Protein A or IMAC capture → ion-exchange → SEC polishing. Yeast-specific host cell proteins (HCPs) are efficiently cleared (>99.99%) with AEX plus low-pH viral inactivation.
11. How are host-cell impurities quantified and controlled?
HCP ELISAs raised against yeast lysates, DNA qPCR (<10 ng/dose), β-glucan assays, and residual mannan quantification by lectin-binding fluorescence. Elise Biopharma’s analytics ensure Saccharomyces cerevisiae CDMO services meet both FDA and EMA impurity thresholds.
12. Can Saccharomyces cerevisiae be used for VLP or particle vaccines?
Absolutely. Yeast self-assembles HBV-like and HPV-like particles. Elise develops design-of-experiment (DoE) matrices linking capsid protein ratios and induction profiles to particle morphology (confirmed by cryo-TEM and DLS).
13. How are process comparability studies handled?
We use scale-down models replicating shear, mixing, and gas transfer. Multi-attribute methods (MAMs) compare glycan, charge variant, and aggregation fingerprints. Statistical process control (SPC) underpins comparability reports for IND/IMPD submissions.
14. Is it possible to co-express multiple subunits or enzymes?
Yes. Elise’s modular pESC dual-promoter system supports co-expression of two to four polypeptides. Stoichiometry is managed via differential promoter strength and codon harmonisation. Ideal for enzyme cascades or heterodimeric fusions.
15. How does Elise address endotoxin and adventitious agent risk?
Yeast naturally lacks endotoxins; risk is restricted to raw-material carryover. All materials are tested under USP <85>/<1085> and viral exclusion verified by 0.2 µm filtration. Regulatory safety arguments cite yeast’s GRAS/QPS classification.
16. What analytical suite supports Saccharomyces cerevisiae CDMO services?
Mass spectrometry (LC-MS, MALDI-TOF), SEC-MALS, CE-SDS, peptide mapping, glycan analysis, DLS, DSC, and FTIR. Potency via SPR/BLI, stability under ICH Q1A/B. Data feeds into 21 CFR Part 11-compliant LIMS and electronic batch records.
17. How scalable are your Saccharomyces cerevisiae CDMO services?
Seed trains up to 2,000 L single-use or 10,000 L stainless-steel lines. We maintain matched geometry and P/V ratios between 2 L, 50 L, 200 L, and 2,000 L. Real-time PAT sensors (Raman, capacitance) maintain equivalent metabolic states.
18. Can metabolic by-products (ethanol, acetate) be controlled?
Yes—via carbon-limited feeding and respiratory quotient (RQ) monitoring. Excess ethanol indicates oxygen limitation; feedforward algorithms adjust airflow and agitation dynamically to maintain RQ ≈ 1.0. This prevents stress glycosylation drift.
19. What regulatory dossiers are typically prepared for yeast programs?
CMC sections include host-cell safety rationales, viral clearance justification, comparability protocols, and process validation reports. Elise drafts documentation aligned with ICH Q5E/Q6B and regional guidelines (FDA CBER, EMA CAT).
20. How sustainable are Saccharomyces cerevisiae CDMO services?
Elise Biopharma integrates glycerol from biodiesel by-products and sugar-cane hydrolysates, capturing >30% carbon reuse efficiency. Waste biomass is converted into single-cell protein feed. ESG metrics are tracked through life-cycle analyses (ISO 14044).
Conclusion
For sponsors who need eukaryotic folding, credible glycosylation options, aggressive timelines, and a pragmatic regulatory path, Saccharomyces cerevisiae CDMO services offer a uniquely balanced platform. The chassis supports vaccines, nutraceutical proteins, Fc-fusions, and industrial enzymes with a safety profile agencies recognise and an upstream/dsp toolkit that engineers can control. When those Saccharomyces cerevisiae CDMO services are executed with specialist strain engineering, quantified oxygen transfer, glyco-aware analytics, and disciplined scale-up, the result is a process that survives real tanks, real audits, and real markets.
If your roadmap demands manufacturability without abandoning biological nuance, anchor it in Saccharomyces cerevisiae CDMO services—the proven yeast workhorse, upgraded for modern bioprocessing.
Email our team at info@elisebiopharma.com
Learn about our –> Yarrowia lipolytica CDMO Services